Study #2016-0193
Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias
MD Anderson Study Status
Not Accepting
Treatment Agent
Pembrolizumab
Description
This randomized phase II trial studies how well pembrolizumab works in treating patients with high risk oral intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia
Study phase:
Phase II
Physician name:
Renata Ferrarotto
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.